Rainmed Medical Limited stock analysis
Want to see HK:2297 full AI Analyst Report?
Rainmed Medical Limited (2297) Stock Price & Analysis
2297 Stock Chart & Stats
- Day’s Range
- HKD 0.14 - HKD 0.15
- 52-Week Range
- HKD 0.14 - HKD 0.33
- Previous Close
- HKD 0.15
- Volume
- N/A
- Average Volume (3M)
- 928.53K
- Market Cap
- HKD 197.59M
- Enterprise Value
- HKD 374.62M
- Total Cash (Recent Filing)
- HKD 129.01M
- Total Debt (Recent Filing)
- HKD 181.94M
- Price to Earnings (P/E)
- ―
- Beta
- 0.34
- Next Earnings
- Apr 01, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Conservative Current Leverage
Modest leverage provides financial flexibility relative to a more debt-funded structure and reduces near-term interest and refinancing pressure. Although losses remain a concern, the current capital base gives Rainmed more capacity to manage operations while addressing its profitability challenges.
Improving Cash-Burn Trend
The reduction in cash burn is an encouraging directional change because it may slow the depletion of financial resources and extend operating runway. This does not establish self-funding, but sustained improvement would strengthen the company’s ability to stabilize without immediately increasing external funding needs.
Clinical-Workflow Product Focus
Rainmed is focused on clearly defined medical-device applications that support routine treatment and patient-care workflows. This product orientation gives the business a specific clinical use case and an identifiable healthcare market position, providing a foundation for future commercialization if execution and economics improve.
Bears Say
Sharp Revenue Contraction
Two consecutive years of substantial revenue contraction indicate weakening commercial scale and make it harder to absorb fixed operating costs. Continued top-line pressure can reduce customer reach, limit investment capacity, and delay the operating leverage needed for the business to move toward sustainable profitability.
Negative Product Economics
A negative gross margin means reported sales did not cover the direct cost of products during 2025, making losses difficult to resolve through revenue growth alone. The company may need meaningful improvement in product economics before additional volume can translate into stronger earnings or cash generation.
Persistent Cash Burn
Persistent negative operating and free cash flow shows that the business has not yet demonstrated the ability to fund operations and investment internally. Continued cash consumption can erode financial resources over time and increase reliance on existing balance-sheet capacity or external funding.
Rainmed Medical Limited News
Rainmed Medical Reshuffles Joint Company Secretary and Compliance Representative
Rainmed Medical Limited ( ($HK:2297) ) has shared an announcement. Rainmed Medical Limited announced a change in its senior corporate governance roles, with joint company secretary and authorised representative Ms.
2297 FAQ
What was Rainmed Medical Limited’s price range in the past 12 months?
What is Rainmed Medical Limited’s market cap?
When is Rainmed Medical Limited’s upcoming earnings report date?
How were Rainmed Medical Limited’s earnings last quarter?
Is Rainmed Medical Limited overvalued?
Does Rainmed Medical Limited pay dividends?
What is Rainmed Medical Limited’s EPS estimate?
How many shares outstanding does Rainmed Medical Limited have?
What happened to Rainmed Medical Limited’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Rainmed Medical Limited?
What is the TipRanks Smart Score and how is it calculated?
Rainmed Medical Limited Stock Smart Score
Company Description
Rainmed Medical Limited
Rainmed Medical Limited is a medical technology firm specializing in the creation, development, and market launch of advanced systems that utilize coronary angiography to assess fractional flow reserve (FFR) and the index of microvascular resistance (IMR). Its offerings include the FlashAngio caFFR System, which accurately determines FFR values by reconstructing a three-dimensional model of the coronary arterial system from two angiographic images. Additionally, the company provides the FlashAngio caIMR System, an innovative non-invasive solution for the diagnosis and treatment of microcirculatory lesions. Rainmed Medical is also engaged in pioneering intelligent angiographic injection technologies, robotic navigation systems for vascular interventions, and flash renal denervation solutions. Established in 2014, the company is headquartered in Suzhou, China.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Yonghui Lyu
- Employees
- 208
- Website
- rainmed.com
- Address
- Room NW-05-502, Suzhou, JS, 215000, CN
Rainmed Medical Limited (2297) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 3 | 5 | 14 |
| Technical Analysis | 3 | 5 | 2 |
| Moving Averages | 0 | 0 | 12 |









